SOX17 expression in tumor‐penetrating vessels in relation to CD8 + T‐cell infiltration in cancer stroma niches
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Hirotaka Yamamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery, Gifu University Hospital, Gifu, Japan. Hauptthemen laut MEDLINE: SOXF Transcription Factors, Tumor Microenvironment, CD8-Positive T-Lymphocytes, Adenocarcinoma of Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Introduction
Sex‐determining region Y‐related high‐mobility group box 17 protein (SOX17), a proangiogenic transcription factor, is specifically expressed in tumor endothelial cells (TECs) of implanted Lewis lung carcinoma. However, the expression profile of SOX17 is largely unknown in human lung cancer. We aimed to elucidate SOX17 expression in cancer cells and the tumor microenvironment of lung adenocarcinoma.
Methods
In the present study, we examined SOX17 expression in whole‐tissue specimens of 83 lung adenocarcinomas by immunohistochemistry.
Results
SOX17 immunoreactivity was minimal in lung adenocarcinoma cells, except in five non‐mucinous adenocarcinomas in situ. SOX17 was also expressed in cultured A549 lung adenocarcinoma cells, which is widely used as a model of malignant alveolar type II epithelial cells. Notably, SOX17 immunoreactivity was found in endothelial cells of tumor‐penetrating vessels in 19 of 83 lung adenocarcinoma tissue specimens, with statistical significance to stromal infiltration of CD8 + T cells ( p < 0.01) but was not associated with the number of tertiary lymph nodes. Although not statistically significant, SOX17 immunoreactivity was related to favorable patient outcomes.
Conclusion
Our findings indicate that SOX17 might play a pleiotropic role in lung adenocarcinoma in cancer cells and stromal niches. SOX17‐mediated CD8 + T‐cell‐rich tumor microenvironment might attract interest in improving the effect of cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Thoracic Surgery, Gifu University Hospital, Gifu, Japan.
- Department of Pathology and Translational Research, Gifu Medical School of Medicine, Gifu, Japan.
- Center for One Medicine Innovative Translational Research, COMIT, Gifu University, Gifu, Japan.
- The United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
ORCID-Profile: Chiemi Saigo, Tamotsu Takeuchi
Förderung
- Japan Society for the Promotion of Science KAKENHI
- Japan Society for the Promotion of Science
Zitieren
APA
Yamamoto, H., Hanamatsu, Y., Saigo, C., Takeuchi, T., & Iwata, H. (2024). SOX17 expression in tumor‐penetrating vessels in relation to CD8 + T‐cell infiltration in cancer stroma niches. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15464
Vancouver
Yamamoto H, Hanamatsu Y, Saigo C, Takeuchi T, Iwata H. SOX17 expression in tumor‐penetrating vessels in relation to CD8 + T‐cell infiltration in cancer stroma niches. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15464
BibTeX
@article{Yamamoto2024,
author = {Yamamoto, Hirotaka and Hanamatsu, Yuki and Saigo, Chiemi and Takeuchi, Tamotsu and Iwata, Hisashi},
title = {SOX17 expression in tumor‐penetrating vessels in relation to CD8 + T‐cell infiltration in cancer stroma niches},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15464}
}
EUVIMED